Skip to main content
Erschienen in: Rheumatology International 2/2009

01.12.2009 | Original Article

Disease burden of psoriatic arthritis compared to rheumatoid arthritis, Hungarian experiment

verfasst von: Valentin Brodszky, Péter Bálint, Pál Géher, László Hodinka, Gábor Horváth, Éva Koó, Márta Péntek, Anna Polgár, Magdolna Seszták, Sándor Szántó, Ilona Ujfalussy, László Gulácsi

Erschienen in: Rheumatology International | Ausgabe 2/2009

Einloggen, um Zugang zu erhalten

Abstract

The objectives of this study were to assess the costs of psoriatic arthritis (PsA) in Hungary and to identify key cost drivers among demographic and clinical variables and to compare cost-of-illness of PsA and rheumatoid arthritis (RA). Cross-sectional retrospective survey of 183 consecutive patients from eight rheumatology centres was conducted. Mean direct medical, direct non medical, indirect and total costs were 1,876, 794, 2,904 and 5,574 euros/patient/year, respectively. Total costs were in significant linear relationship with health assessment questionnaire score and psoriatic area severity index. Costs of RA were higher in all domains than of PsA. Our study was the first from the Eastern European region that provides cost-of-illness data on PsA. Our study revealed that functional status and severity of skin symptoms were the key cost drivers. The costs of PsA in Hungary were lower than in the high-income European countries.
Literatur
2.
Zurück zum Zitat Ackermann C, Kavanaugh A (2008) Economic burden of psoriatic arthritis. Pharmacoeconomics 26:121–129CrossRefPubMed Ackermann C, Kavanaugh A (2008) Economic burden of psoriatic arthritis. Pharmacoeconomics 26:121–129CrossRefPubMed
4.
Zurück zum Zitat Huscher D, Merkesdal S, Thiele K, Zeidler H, Schneider M, Zink A, German Collaborative Arthritis C (2006) Cost of illness in rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and systemic lupus erythematosus in Germany. Ann Rheum Dis 65:1175–1183. doi:10.1136/ard.2005.046367 CrossRefPubMed Huscher D, Merkesdal S, Thiele K, Zeidler H, Schneider M, Zink A, German Collaborative Arthritis C (2006) Cost of illness in rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and systemic lupus erythematosus in Germany. Ann Rheum Dis 65:1175–1183. doi:10.​1136/​ard.​2005.​046367 CrossRefPubMed
7.
Zurück zum Zitat Lovas K, Koó É, Whalley D, Meads D, Kaló Z, McKenna SP (2002) Az arthritis psoriaticában szenvedő betegeknek kidolgozott életminőség-kérdőív magyarországi adaptációja. LAM 12:389–395 Lovas K, Koó É, Whalley D, Meads D, Kaló Z, McKenna SP (2002) Az arthritis psoriaticában szenvedő betegeknek kidolgozott életminőség-kérdőív magyarországi adaptációja. LAM 12:389–395
8.
Zurück zum Zitat Bruce B, Fries JF (2003) The stanford health assessment questionnaire: a review of its history, issues, progress, and documentation. J Rheumatol 30:167–178PubMed Bruce B, Fries JF (2003) The stanford health assessment questionnaire: a review of its history, issues, progress, and documentation. J Rheumatol 30:167–178PubMed
9.
Zurück zum Zitat Pentek M, Szekanecz Z, Czirjak L, Poor G, Rojkovich B, Polgar A, Genti G, Kiss CG, Sandor Z, Majer I, Brodszky V, Gulacsi L (2008) Impact of disease progression on health status, quality of life and costs in rheumatoid arthritis in Hungary. Orv Hetil 149:733–741. doi:10.1556/OH.2008.28294 CrossRefPubMed Pentek M, Szekanecz Z, Czirjak L, Poor G, Rojkovich B, Polgar A, Genti G, Kiss CG, Sandor Z, Majer I, Brodszky V, Gulacsi L (2008) Impact of disease progression on health status, quality of life and costs in rheumatoid arthritis in Hungary. Orv Hetil 149:733–741. doi:10.​1556/​OH.​2008.​28294 CrossRefPubMed
10.
Zurück zum Zitat Péntek M, Kobelt G, Czirjak L, Szekanecz Z, Rojkovich B, Polgar A, Genti G, Kiss CG, Brodszky V, Majer I, Gulacsi L (2007) Costs of rheumatoid arthritis in Hungary. J Rheumatol 34:1437PubMed Péntek M, Kobelt G, Czirjak L, Szekanecz Z, Rojkovich B, Polgar A, Genti G, Kiss CG, Brodszky V, Majer I, Gulacsi L (2007) Costs of rheumatoid arthritis in Hungary. J Rheumatol 34:1437PubMed
11.
Zurück zum Zitat Wallenius M, Skomsvoll JF, Koldingsnes W, Rodevand E, Mikkelsen K, Kaufmann C, Kvien TK (2008) Work disability and health-related quality of life in males and females with psoriatic arthritis. Ann Rheum Dis. doi:10.1080/03009740802400594 Wallenius M, Skomsvoll JF, Koldingsnes W, Rodevand E, Mikkelsen K, Kaufmann C, Kvien TK (2008) Work disability and health-related quality of life in males and females with psoriatic arthritis. Ann Rheum Dis. doi:10.​1080/​0300974080240059​4
12.
Zurück zum Zitat Bansback NJ, Ara R, Barkham N, Brennan A, Fraser AD, Conway P, Reynolds A, Emery P (2006) Estimating the cost and health status consequences of treatment with TNF antagonists in patients with psoriatic arthritis. Rheumatology (Oxford) 45:1029–1038. doi:10.1093/rheumatology/kel147 CrossRef Bansback NJ, Ara R, Barkham N, Brennan A, Fraser AD, Conway P, Reynolds A, Emery P (2006) Estimating the cost and health status consequences of treatment with TNF antagonists in patients with psoriatic arthritis. Rheumatology (Oxford) 45:1029–1038. doi:10.​1093/​rheumatology/​kel147 CrossRef
13.
Zurück zum Zitat Bravo Vergel Y, Hawkins NS, Claxton K, Asseburg C, Palmer S, Woolacott N, Bruce IN, Sculpher MJ (2007) The cost-effectiveness of etanercept and infliximab for the treatment of patients with psoriatic arthritis. Rheumatology (Oxford) 46:1729–1735. doi:10.1093/rheumatology/kem221 CrossRef Bravo Vergel Y, Hawkins NS, Claxton K, Asseburg C, Palmer S, Woolacott N, Bruce IN, Sculpher MJ (2007) The cost-effectiveness of etanercept and infliximab for the treatment of patients with psoriatic arthritis. Rheumatology (Oxford) 46:1729–1735. doi:10.​1093/​rheumatology/​kem221 CrossRef
14.
Zurück zum Zitat Zink A, Thiele K, Huscher D, Listing J, Sieper J, Krause A, Gromnica-Ihle E, von Hinueber U, Wassenberg S, Genth E, Schneider M (2006) Healthcare and burden of disease in psoriatic arthritis. A comparison with rheumatoid arthritis and ankylosing spondylitis. J Rheumatol 33:86–90PubMed Zink A, Thiele K, Huscher D, Listing J, Sieper J, Krause A, Gromnica-Ihle E, von Hinueber U, Wassenberg S, Genth E, Schneider M (2006) Healthcare and burden of disease in psoriatic arthritis. A comparison with rheumatoid arthritis and ankylosing spondylitis. J Rheumatol 33:86–90PubMed
15.
Zurück zum Zitat Olivieri I, de Portu S, Salvarani C, Cauli A, Lubrano E, Spadaro A, Cantini F, Cutro MS, Mathieu A, Matucci-Cerinic M, Pappone N, Punzi L, Scarpa R, Mantovani LG (2008) The psoriatic arthritis cost evaluation study: a cost-of-illness study on tumour necrosis factor inhibitors in psoriatic arthritis patients with inadequate response to conventional therapy. Rheumatology (Oxford) 47:1664–1670. doi:10.1093/rheumatology/ken320 CrossRef Olivieri I, de Portu S, Salvarani C, Cauli A, Lubrano E, Spadaro A, Cantini F, Cutro MS, Mathieu A, Matucci-Cerinic M, Pappone N, Punzi L, Scarpa R, Mantovani LG (2008) The psoriatic arthritis cost evaluation study: a cost-of-illness study on tumour necrosis factor inhibitors in psoriatic arthritis patients with inadequate response to conventional therapy. Rheumatology (Oxford) 47:1664–1670. doi:10.​1093/​rheumatology/​ken320 CrossRef
Metadaten
Titel
Disease burden of psoriatic arthritis compared to rheumatoid arthritis, Hungarian experiment
verfasst von
Valentin Brodszky
Péter Bálint
Pál Géher
László Hodinka
Gábor Horváth
Éva Koó
Márta Péntek
Anna Polgár
Magdolna Seszták
Sándor Szántó
Ilona Ujfalussy
László Gulácsi
Publikationsdatum
01.12.2009
Verlag
Springer-Verlag
Erschienen in
Rheumatology International / Ausgabe 2/2009
Print ISSN: 0172-8172
Elektronische ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-009-0936-1

Weitere Artikel der Ausgabe 2/2009

Rheumatology International 2/2009 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.